{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T23:27:55Z","timestamp":1794871675589,"version":"4.9.1"},"reference-count":37,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"8","license":[{"start":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T00:00:00Z","timestamp":1703721600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Mutations in five canonical Ras pathway genes (NF1, NRAS, KRAS, PTPN11 and CBL) are detected in nearly 90% of patients with juvenile myelomonocytic leukemia (JMML), a frequently fatal malignant neoplasm of early childhood. In this report, we describe seven patients diagnosed with SH2B3-mutated JMML, including five patients who were found to have initiating, loss-of-function mutations in the gene. SH2B3 encodes the adaptor protein LNK, a negative regulator of normal hematopoiesis upstream of the Ras pathway. These mutations were identified to be germline, somatic or a combination of both. Loss of function of LNK, which has been observed in other myeloid malignancies, results in abnormal proliferation of hematopoietic cells due to cytokine hypersensitivity and activation of the JAK\/STAT signaling pathway. In vitro studies of induced pluripotent stem cell-derived JMML-like hematopoietic progenitor cells also demonstrated sensitivity of SH2B3-mutated hematopoietic progenitor cells to JAK inhibition. Lastly, we describe two patients with JMML and SH2B3 mutations who were treated with the JAK1\/2 inhibitor ruxolitinib. This report expands the spectrum of initiating mutations in JMML and raises the possibility of targeting the JAK\/STAT pathway in patients with SH2B3 mutations.<\/jats:p>","DOI":"10.3324\/haematol.2023.283776","type":"journal-article","created":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T02:52:06Z","timestamp":1703731926000},"page":"2533-2541","source":"Crossref","is-referenced-by-count":8,"title":["LNK\/&lt;i&gt;SH2B3&lt;\/i&gt; as a novel driver in juvenile myelomonocytic leukemia"],"prefix":"10.3324","volume":"109","author":[{"given":"Astrid","family":"Wintering","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Hecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric B.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juwita","family":"H\u00fcbner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney","family":"Abelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kira","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa E.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl A.C.","family":"Peretz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah L.","family":"French","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Ann","family":"Maguire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chintan","family":"Jobaliya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta Rojas","family":"Vasquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Dulman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eneida","family":"Nemecek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilary","family":"Haines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Hammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa","family":"El Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott C.","family":"Kogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zied","family":"Abdullaev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farid F.","family":"Chehab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah K.","family":"Tasian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine C.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mignon L.","family":"Loh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliot","family":"Stieglitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,12,28]]},"reference":[{"key":"64407","doi-asserted-by":"crossref","unstructured":"Locatelli F, Niemeyer CM. How I treat juvenile myelomonocytic leukemia. Blood. 2018; 125(7):1083-1091.","DOI":"10.1182\/blood-2014-08-550483"},{"key":"64408","doi-asserted-by":"crossref","unstructured":"Emanuel PD, Bates LJ, Castleberry RP, Gualtieri RJ, Zuckerman KS. Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors. Blood. 1991; 77(5):925-929.","DOI":"10.1182\/blood.V77.5.925.bloodjournal775925"},{"key":"64409","doi-asserted-by":"crossref","unstructured":"Stieglitz E, Taylor-Weiner AN, Chang TY. The genomic landscape of juvenile myelomonocytic leukemia. Nat Genet. 2015; 47(11):1326-1333.","DOI":"10.1038\/ng.3400"},{"key":"64410","doi-asserted-by":"crossref","unstructured":"Caye A, Strullu M, Guidez F. Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network. Nat Genet. 2015; 47(11):1334-1340.","DOI":"10.1038\/ng.3420"},{"key":"64411","doi-asserted-by":"crossref","unstructured":"Murakami N, Okuno Y, Yoshida K. Integrated molecular profiling of juvenile myelomonocytic leukemia. Blood. 2018; 131(14):1576-1586.","DOI":"10.1182\/blood-2017-07-798157"},{"key":"64412","doi-asserted-by":"crossref","unstructured":"Wintering A, Dvorak CC, Stieglitz E, Loh ML. Juvenile myelomonocytic leukemia in the molecular era: a clinician\u2019s guide to diagnosis, risk-stratification, and treatment. Blood Adv. 2021; 5(22):4783-4793.","DOI":"10.1182\/bloodadvances.2021005117"},{"key":"64413","doi-asserted-by":"crossref","unstructured":"Buijs A, Bruin M. Fusion of FIP1L1 and RARA as a result of a novel t(4;17)(q12;q21) in a case of juvenile myelomonocytic leukemia. Leukemia. 2007; 21(5):1104-1108.","DOI":"10.1038\/sj.leu.2404596"},{"key":"64414","doi-asserted-by":"crossref","unstructured":"Morerio C, Acquila M, Rosanda C. HCMOGT-1 is a novel fusion partner to PDGFRB in juvenile myelomonocytic leukemia with t(5;17)(q33;p11.2). Cancer Res. 2004; 64(8):2649-2651.","DOI":"10.1158\/0008-5472.CAN-03-4026"},{"key":"64415","doi-asserted-by":"crossref","unstructured":"Byrgazov K, Kastner R, Dworzak M. A novel fusion gene NDEL1-Pdgfrb in a patient with JMML with a new variant of TKI-resistant mutation in the kinase domain of PDGFR\u03b2. Blood. 2014; 124(21):613.","DOI":"10.1182\/blood.V124.21.613.613"},{"key":"64416","doi-asserted-by":"crossref","unstructured":"Chao AK, Meyer JA, Lee AG. Fusion driven JMML: a novel CCDC88C\u2013FLT3 fusion responsive to sorafenib identified by RNA sequencing. Leukemia. 2020; 34(2):662-666.","DOI":"10.1038\/s41375-019-0549-y"},{"key":"64417","doi-asserted-by":"crossref","unstructured":"Gratias EJ, Liu YL, Meleth S, Castleberry RP, Emanuel PD. Activating FLT3 mutations are rare in children with juvenile myelomonocytic leukemia. Pediatr Blood Cancer. 2005; 44(2):142-146.","DOI":"10.1002\/pbc.20176"},{"key":"64418","doi-asserted-by":"crossref","unstructured":"Behnert A, Meyer J, Parsa J-Y. Exploring the genetic and epigenetic origins of juvenile myelomonocytic leukemia using newborn screening samples. Leukemia. 2022; 36(1):279-282.","DOI":"10.1038\/s41375-021-01331-0"},{"key":"64419","doi-asserted-by":"crossref","unstructured":"Sch\u00f6nung M, Meyer J, N\u00f6llke P. International consensus definition of DNA methylation subgroups in juvenile myelomonocytic leukemia. Clin Cancer Res. 2020; 27(1):158-168.","DOI":"10.1158\/1078-0432.CCR-20-3184"},{"key":"64420","doi-asserted-by":"crossref","unstructured":"Gandre-Babbe S, Paluru P, Aribeana C. Patient-derived induced pluripotent stem cells recapitulate hematopoietic abnormalities of juvenile myelomonocytic leukemia. Blood. 2013; 121(24):4925-4929.","DOI":"10.1182\/blood-2013-01-478412"},{"key":"64421","doi-asserted-by":"crossref","unstructured":"Mills JA, Paluru P, Weiss MJ, Gadue P, French DL. Hematopoietic differentiation of pluripotent stem cells in culture. Methods Mol Biol. 2014; 1185:181-194.","DOI":"10.1007\/978-1-4939-1133-2_12"},{"key":"64422","doi-asserted-by":"crossref","unstructured":"Velazquez L, Cheng AM, Fleming HE. Cytokine signaling and hematopoietic homeostasis are disrupted in Lnk-deficient mice. J Exp Med. 2002; 195(12):1599-1611.","DOI":"10.1084\/jem.20011883"},{"key":"64423","doi-asserted-by":"crossref","unstructured":"Li Y, He X, Schembri-King J, Jakes S, Hayashi J. Cloning and characterization of human Lnk, an adaptor protein with pleckstrin homology and Src homology 2 domains that can inhibit T cell activation. J Immunol. 2000; 164(10):5199-5206.","DOI":"10.4049\/jimmunol.164.10.5199"},{"key":"64424","doi-asserted-by":"crossref","unstructured":"Gery S, Gueller S, Chumakova K, Kawamata N, Liu L, Koeffler HP. Adaptor protein Lnk negatively regulates the mutant MPL, MPLW515L associated with myeloproliferative disorders. Blood. 2007; 110(9):3360-3364.","DOI":"10.1182\/blood-2007-05-089326"},{"key":"64425","doi-asserted-by":"crossref","unstructured":"Tong W, Zhang J, Lodish HF. Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways. Blood. 2005; 105(12):4604-4612.","DOI":"10.1182\/blood-2004-10-4093"},{"key":"64426","doi-asserted-by":"crossref","unstructured":"Bersenev A, Wu C, Balcerek J, Tong W. Lnk controls mouse hematopoietic stem cell self-renewal and quiescence through direct interactions with JAK2. J Clin Invest. 2008; 118(8):2832-2844.","DOI":"10.1172\/JCI35808"},{"key":"64427","doi-asserted-by":"crossref","unstructured":"Takaki S, Morita H, Tezuka Y, Takatsu K. Enhanced hematopoiesis by hematopoietic progenitor cells lacking intracellular adaptor protein, Lnk. J Exp Med. 2002; 195(2):151-160.","DOI":"10.1084\/jem.20011170"},{"key":"64428","doi-asserted-by":"crossref","unstructured":"Takaki S, Sauer K, Iritani BM. Control of B cell production by the adaptor protein lnk. Definition of a conserved family of signal-modulating proteins. Immunity. 2000; 13(5):599-609.","DOI":"10.1016\/S1074-7613(00)00060-1"},{"key":"64429","doi-asserted-by":"crossref","unstructured":"Takizawa H, Eto K, Yoshikawa A, Nakauchi H, Takatsu K, Takaki S. Growth and maturation of megakaryocytes is regulated by Lnk\/Sh2b3 adaptor protein through crosstalk between cytokine- and integrin-mediated signals. Exp Hematol. 2008; 36(7):897-906.","DOI":"10.1016\/j.exphem.2008.02.004"},{"key":"64430","doi-asserted-by":"crossref","unstructured":"Maslah N, Cassinat B, Verger E, Kiladjian JJ, Velazquez L. The role of LNK\/SH2B3 genetic alterations in myeloproliferative neoplasms and other hematological disorders. Leukemia. 2017; 31(8):1661-1670.","DOI":"10.1038\/leu.2017.139"},{"key":"64431","doi-asserted-by":"crossref","unstructured":"McMullin MF, Cario H. LNK mutations and myeloproliferative disorders. Am J Hematol. 2016; 91(2):248-251.","DOI":"10.1002\/ajh.24259"},{"key":"64432","doi-asserted-by":"crossref","unstructured":"Gundabolu K, Dave BJ, Alvares CJ. The missing LNK: evolution from cytosis to chronic myelomonocytic leukemia in a patient with multiple sclerosis and germline SH2B3 mutation. Case Rep Genet. 2022; 2022:6977041.","DOI":"10.1155\/2022\/6977041"},{"key":"64433","doi-asserted-by":"crossref","unstructured":"Perez-Garcia A, Ambesi-Impiombato A, Hadler M. Genetic loss of SH2B3 in acute lymphoblastic leukemia. Blood. 2013; 122(14):2425-2432.","DOI":"10.1182\/blood-2013-05-500850"},{"key":"64434","doi-asserted-by":"crossref","unstructured":"Pardanani A, Lasho T, Finke C, Oh ST, Gotlib J, Tefferi A. LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations. Leukemia. 2010; 24(10):1713-1718.","DOI":"10.1038\/leu.2010.163"},{"key":"64435","doi-asserted-by":"crossref","unstructured":"Zhang J, Ding L, Holmfeldt L. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature. 2012; 481(7380):157-163.","DOI":"10.1038\/nature10725"},{"key":"64436","doi-asserted-by":"crossref","unstructured":"Stieglitz E, Mazor T, Olshen AB. Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia. Nat Commun. 2017; 8(1):1-8.","DOI":"10.1038\/s41467-017-02178-9"},{"key":"64437","doi-asserted-by":"crossref","unstructured":"Stephens K, Weaver M, Leppig KA. Interstitial uniparental isodisomy at clustered breakpoint intervals is a frequent mechanism of NF1 inactivation in myeloid malignancies. Blood. 2006; 108(5):1684-1689.","DOI":"10.1182\/blood-2005-11-011486"},{"key":"64438","doi-asserted-by":"crossref","unstructured":"Le DT, Kong N, Zhu Y. Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder. Blood. 2004; 103(11):4243-4250.","DOI":"10.1182\/blood-2003-08-2650"},{"key":"64439","doi-asserted-by":"crossref","unstructured":"Xu L, Feng J, Gao G, Tang H. Momelotinib for the treatment of myelofibrosis. Expert Opin Pharmacother. 2019; 20(16):1943-1951.","DOI":"10.1080\/14656566.2019.1657093"},{"key":"64440","doi-asserted-by":"crossref","unstructured":"Griesshammer M, Sadjadian P. The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium. Expert Opin Pharmacother. 2017; 18(18):1929-1938.","DOI":"10.1080\/14656566.2017.1404574"},{"key":"64441","doi-asserted-by":"crossref","unstructured":"Pardanani A, Vannucchi AM, Passamonti F, Cervantes F, Barbui T, Tefferi A. JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. Leukemia. 2011; 25(2):218-225.","DOI":"10.1038\/leu.2010.269"},{"key":"64442","doi-asserted-by":"crossref","unstructured":"Tasian SK, Casas JA, Posocco D. Mutation-specific signaling profiles and kinase inhibitor sensitivities of juvenile myelomonocytic leukemia revealed by induced pluripotent stem cells. Leukemia. 2018; 33(1):181-190.","DOI":"10.1038\/s41375-018-0169-y"},{"key":"64443","doi-asserted-by":"crossref","unstructured":"Jahn K, Kuipers J, Beerenwinkel N. Tree inference for single-cell data. Genome Biol. 2016; 17:86.","DOI":"10.1186\/s13059-016-0936-x"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283776\/76484","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283776\/77345","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11389\/76484","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:05:28Z","timestamp":1794045928000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.283776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,28]]},"references-count":37,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.283776","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,28]]}}}